The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
- PMID: 35836811
- PMCID: PMC9274751
- DOI: 10.7150/thno.71813
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Abstract
Despite the elucidation of the pathways behind the development of aortic stenosis (AS), there remains no effective medical treatment to slow or reverse its progress. Instead, the gold standard of care in severe or symptomatic AS is replacement of the aortic valve. Oxidative stress is implicated, both directly as well as indirectly, in lipid infiltration, inflammation and fibro-calcification, all of which are key processes underlying the pathophysiology of degenerative AS. This culminates in the breakdown of the extracellular matrix, differentiation of the valvular interstitial cells into an osteogenic phenotype, and finally, calcium deposition as well as thickening of the aortic valve. Oxidative stress is thus a promising and potential therapeutic target for the treatment of AS. Several studies focusing on the mitigation of oxidative stress in the context of AS have shown some success in animal and in vitro models, however similar benefits have yet to be seen in clinical trials. Statin therapy, once thought to be the key to the treatment of AS, has yielded disappointing results, however newer lipid lowering therapies may hold some promise. Other potential therapies, such as manipulation of microRNAs, blockade of the renin-angiotensin-aldosterone system and the use of dipeptidylpeptidase-4 inhibitors will also be reviewed.
Keywords: Severe aortic stenosis; oxidative stress; reactive oxidative species.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
Similar articles
-
The lipid theory in the pathogenesis of calcific aortic stenosis.Nutr Metab Cardiovasc Dis. 2015 Jun;25(6):519-25. doi: 10.1016/j.numecd.2015.02.001. Epub 2015 Feb 12. Nutr Metab Cardiovasc Dis. 2015. PMID: 25816732 Review.
-
Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells.Circulation. 2017 May 16;135(20):1935-1950. doi: 10.1161/CIRCULATIONAHA.116.024270. Epub 2017 Feb 8. Circulation. 2017. PMID: 28179397
-
Diabetes concomitant to aortic stenosis is associated with increased expression of NF-κB and more pronounced valve calcification.Diabetologia. 2021 Nov;64(11):2562-2574. doi: 10.1007/s00125-021-05545-w. Epub 2021 Sep 7. Diabetologia. 2021. PMID: 34494136 Free PMC article.
-
[Degenerative aortic valve stenosis: looking for a pharmacological prevention].G Ital Cardiol (Rome). 2023 Apr;24(4):293-304. doi: 10.1714/4004.39820. G Ital Cardiol (Rome). 2023. PMID: 36971173 Review. Italian.
-
Transforming growth factor-β1 promotes fibrosis but attenuates calcification of valvular tissue applied as a three-dimensional calcific aortic valve disease model.Am J Physiol Heart Circ Physiol. 2020 Nov 1;319(5):H1123-H1141. doi: 10.1152/ajpheart.00651.2019. Epub 2020 Sep 28. Am J Physiol Heart Circ Physiol. 2020. PMID: 32986963
Cited by
-
Genetic causal association between lipidomic profiles, inflammatory proteomics, and aortic stenosis: a Mendelian randomization investigation.Eur J Med Res. 2024 Aug 31;29(1):446. doi: 10.1186/s40001-024-02014-z. Eur J Med Res. 2024. PMID: 39217396 Free PMC article.
-
Lipoprotein(a) As a Potential Predictive Factor for Earlier Aortic Valve Replacement in Patients with Bicuspid Aortic Valve.Biomedicines. 2023 Jun 25;11(7):1823. doi: 10.3390/biomedicines11071823. Biomedicines. 2023. PMID: 37509461 Free PMC article.
-
Calcific aortic valve disease augments vesicular microRNA-145-5p to regulate the calcification of valvular interstitial cells via cellular crosstalk.Basic Res Cardiol. 2025 Aug 22. doi: 10.1007/s00395-025-01133-w. Online ahead of print. Basic Res Cardiol. 2025. PMID: 40847220
-
Association Between Inflammatory Arthritis, Genetic Risk, and the Long-Term Risk of Degenerative Aortic Stenosis: A Prospective Cohort Study.J Am Heart Assoc. 2025 Feb 18;14(4):e038815. doi: 10.1161/JAHA.124.038815. Epub 2025 Feb 8. J Am Heart Assoc. 2025. PMID: 39921509 Free PMC article.
-
Plasma levels of NO-related pathway molecules to predict post-transcatheter aortic valve implantation major adverse cardiovascular events: a prospective, multicenter study.Postepy Kardiol Interwencyjnej. 2025 Jun 4;21(2):211-220. doi: 10.5114/aic.2025.151798. eCollection 2025 Jun. Postepy Kardiol Interwencyjnej. 2025. PMID: 40656163 Free PMC article.
References
-
- Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al; Global Burden of Disease Study 2017 Nonrheumatic Valve Disease Collaborators. Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990-2017. Circulation. 2020 May 26;141(21):1670–1680. - PubMed
-
- Akahori H, Tsujino T, Masuyama T, Ishihara M. Mechanisms of aortic stenosis. J Cardiol. 2018 Mar;71(3):215–220. - PubMed
-
- Writing Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd. et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):e25–e197. - PubMed
-
- Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res. 2011 Jun 10;108(12):1510–1524. - PubMed
-
- Myasoedova VA, Ravani AL, Frigerio B, Valerio V, Moschetta D, Songia P. et al. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacol Res. 2018 Oct;136:74–82. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials